Latest news stories about centronuclear and myotubular myopathy can be found on this page. To see news stories from previous years please see the news archive pages.
- Boy with terminal disease gets his wish – a trip to Disneyland – but family still looking for support
Nanaimo News Bulletin, 11 December 2018 - Local business sponsoring family to go to Disneyland
My Campbell River Now, 9 December 2018 - Myotubular Myopathy Progression Molecule ID’d
Rehab Management, 27 November 2018 - A molecule for fighting muscular paralysis
BioNewsCentral, 19 November 2018 - Tamoxifen: from Breast Cancer it switches to genetic muscle disease
Medicomunicare, 19 November 2018 - Breast Cancer drug slows progress of fatal muscle disorder
Genetic Engineering and Biotechnology News, 19 November 2018 - Researchers identify molecule to fight myotubular myopathy
News Medical Life Sciences, 19 November 2018 - Audentes Therapeutics Presents New Positive Interim Data from ASPIRO, the Phase 1/2 Clinical Trial of AT132 in Patients with X-linked Myotubular Myopathy, at 23rd International Annual Congress of the World Muscle Society
Audentes, 5 October 2018 - Audentes Therapeutics to Participate in Upcoming Investor Conferences
MarketsInsider, 26 September 2018 - Audentes Therapeutics to Present New Data from ASPIRO, the Phase 1/2 Clinical Trial of AT132 in Patients with X-Linked Myotubular Myopathy, at the 23rd International Congress of the World Muscle Society
PR Newswire, 24 September 2018 - Alan Titchmarsh’s Love Your Garden makeover has transformed life for Haggerston family
Hackney Gazette, 19 September 2018 - Audentes Therapeutics to Participate in Upcoming Investor Conferences
PR Newswire, 29 August 2018 - FDA Grants RMAT Designation to AT132 for Patients with X-Linked Myotubular Myopathy
Rare Disease Report, 21 August 2018 - Audentes Announces Regenerative Medicine Advanced Therapy (RMAT) Designation Granted by the FDA to AT132 for the Treatment of X-Linked Myotubular Myopathy
Markets Insider, 21 August 2018 - Audentes (BOLD) Announces RMAT Designation Granted by FDA to AT132 for Treatment of X-Linked Myotubular Myopathy
StreetInsider, 21 August 2018, - Audentes Announces Regenerative Medicine Advanced Therapy (RMAT) Designation Granted by the FDA to AT132 for the Treatment of X-Linked Myotubular Myopathy
Audentes, 21 August 2018 - Parents campaign to allow child with rare syndrome to leave home: ‘Home care is not private jail’
Globo.com, 16 August 2018 - Audentes Therapeutics (BOLD) CEO Matt Patterson on Q2 2018 Results – Earnings Call Transcript
Seeking Alpha, 7 August 2018 - Audentes Therapeutics Reports Second Quarter 2018 Financial Results and Provides Update on ASPIRO, the Phase 1/2 Clinical Trial of AT132 in Patients with X-Linked Myotubular Myopathy
Markets Insider, 7 August 2018 - Audentes to Release Second Quarter 2018 Financial Results and Provide Update on ASPIRO, the Phase 1/2 study of AT132 in Patients with X-Linked Myotubular Myopathy
Markets Insider, 31 July 2018 - Audentes to Release Second Quarter 2018 Financial Results and Provide Update on ASPIRO, the Phase 1/2 study of AT132 in Patients with X-Linked Myotubular Myopathy
PR Newswire, 31 July 2018 - Dynacure collects $55m
Global University Venturing, 10 July 2018 - Dynacure names Chris Freitag (MD) Chief Medical Officer
Dynacure, 10 July 2018 - With tech from Spinraza’s maker, French startup Dynacure gets $55M to tackle neuromuscular disease
Endspoints News, 6 July 2018 - Ionis-backed Dynacure bags €47M to start clinical trials
FierceBiotech, 6 July 2018 - France’s Dynacure Gets VC Backing To Progress Antisense Candidate For Myopathy
Scrip Pharma Intelligence, 6 July 2018 - Dynacure secures $55 million Series A round for rare genetic disease treatment
MedCityNews, 6 July 2018 - Dynacure secures €47 million financing to advance lead program into clinical development
Dynacure, 6 July 2018 - Friends take on wacky rally to raise money for disabled riders
Hereford Times, 3 July 2018 - Audentes Announces Priority Medicines (PRIME) Designation Granted by the European Medicines Agency to AT132 for the treatment of X-Linked Myotubular Myopathy
http://investors.audentestx.com, 5 June 2018 - New play area opens at West Belfast centre for young people with complex needs
https://www.belfastlive.co.uk/, 2 June 2018 - ‘We’ll always have unanswered questions about how our Liam died’
https://www.communitynews.com.au/, 25 May 2018 - ‘Dad, dad, dad’ – what disabled Middlesbrough lad said before death
http://www.thenorthernecho.co.uk/news/, 24 May 2018 - Bushmead couple to run in memory of son and to raise funds for MDWA
https://www.gazettelive.co.uk/, 24 May 2018 - Opinions differ over cause of death of severely disabled Middlesbrough man
https://www.gazettelive.co.uk/, 22 May 2018 - Severely disabled Middlesbrough man died following a suspected allergic reaction
http://www.thenorthernecho.co.uk/, 22 May 2018 - Gene replacement therapy that works in dogs to be tested in children
https://newsroom.uw.edu/, 18 May 2018 - Audentes Announces Continuing Positive Data from First Dose Cohort of ASPIRO, a Phase 1/2 Clinical Trial of AT132 in Patients With X-Linked Myotubular Myopathy
https://www.prnewswire.com/, 16 May 2018 - Audentes Therapeutics to Present at the Bank of America Merrill Lynch Health Care Conference 2018
https://pilotonline.com, 9 May 2018 - Audentes Therapeutics Reports First Quarter 2018 Financial Results and Provides Corporate Update
http://investors.audentestx.com, 9 May 2018 - Audentes Therapeutics’ Upcoming Catalysts
https://seekingalpha.com, 3 May 2018 - Audentes Therapeutics to Release First Quarter 2018 Financial Results and Provide Corporate Update
https://www.pharmiweb.com, 2 May 2018 - Belinda Cowling (PhD) joins Dynacure as Head of Research
Dynacure, 30 April 2018 - Audentes Therapeutics Announces Presentation of Data at the 21st Annual Meeting of the American Society of Gene and Cell Therapy
https://www.prnewswire.com, 30 April 2018 - Audentes Therapeutics Announces Presentation of Data at the 21st Annual Meeting of the American Society of Gene and Cell Therapy
http://markets.businessinsider.com, 30 April 2018 - Audentes Therapeutics Reports Fourth Quarter 2017 and Full Year Financial Results and Provides Corporate Update
https://www.prnewswire.com, 8 March 2018 - Kids With Physical Disabilities Deserve Respect and Admiration
https://www.newswire.ca, 1 March 2018 - Photographer donates time, talent to families who have lost a child
https://www.dailyrepublic.com, March 2018 - Audentes Therapeutics Joins Global Organizations In Recognizing Rare Disease Day 2018
https://www.prnewswire.com/news-releases, 28 February 2018 - New strategy for the treatment of myotubular myopathy
http://www.igbmc.fr/society/actualite/282, 14 February 2018 - Treating Rare Hereditary Muscle Disorders: New MYOCURE Interviews Provide Research Insights
http://cordis.europa.eu, 16 January 2018 - Myotubular Myopathy Clinical Trials Showing Early Success in Children
http://naiaonline.org, 8 January 2018 - Gene-Therapy Update: Mixed Results Don’t Dim Hopes
https://www.barrons.com, 8 January 2018 - Groundbreaking treatment developed at UW Medicine
http://www.kiro7.com, 5 January 2018 - Audentes Announces Positive Interim Data from First Dose Cohort of ASPIRO, a Phase 1/2 Clinical Trial of AT132 in Patients With X-Linked Myotubular Myopathy
https://www.prnewswire.com, 4 January 2018
centronuclear.org.uk 